[CAR-T immunotherapy, a regulatory milestone]

Abstract

The first therapy based on chimeric antigen receptors has been approved by the FDA. It gives excellent results in recurrent paediatric ALL; its cost is very high but fairly consistent with the clinical benefit (long term remission approaching a cure). In spite of their complexity and cost, CAR-T therapies will probably end up playing a very significant role in cancer therapy.